Researchers
Rudolph M. Navari, M.D., Ph.D., F.A.C.P.
Director, Walther Cancer Research Center
Assistant Dean and Director, Indiana University School of Medicine South Bend
Contact Information
- Office: 224 Raclin-Carmichael Hall
- Email: navari.1@nd.edu
- Phone: (574) 631-3793
Biography
Dr. Navari received the Ph.D. degree at the University of Virginia, and the M.D. degree at the Medical College of Virginia. He received training in internal medicine at the University of Alabama in Birmingham, and was a Fellow in Hematology and Oncology at the Fred Hutchinson Cancer Research Center, University of Washington School of Medicine. He is board certified in internal medicine and medical oncology. From 1983 to 1998, he served on the Clinical Faculty of the University of Alabama Birmingham and was a practicing medical oncologist in the Simon-Williamson Clinic. During this time, he was Chairman of the Department of Medicine and President of the Simon-Williamson Clinic, Director of the Bone Marrow Transplantation Program and Director of the Comprehensive Cancer Program at Baptist Medical Center. In 1997, he was elected a Fellow of the American College of Physicians. During 1998-99, he was a Fellow in Clinical Medical Ethics in the MacLean Center for Clinical Medical Ethics at the University of Chicago. He joined the faculty of the College of Science of the University of Notre Dame in 1999 as Director of the Walther Cancer Research Center. He was appointed Associate Dean, College of Science, in 2000. In 2005, he became Professor of Medicine, Assistant Dean and Director, Indiana University School of Medicine South Bend.
Research Interests
Dr. Navari's research interests include supportive care in clinical oncology, development of antiemetics, palliative care, and the doctor-patient relationship in clinical oncology. He has published over eighty peer reviewed articles, with the most recent dealing with supportive care issues in clinical oncology.
Publications
Navari RM. Inhibiting substance P pathway for prevention of chemotherapy-induced emesis: Preclinical data, clinical trials of neurokinin-1 receptor antagonists. Support Cancer Ther 2004; 1: 89-96.
Navari RM. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. Cancer Invest 2004; 22: 569-576.
Passik S, Navari RM, Loehrer PJ, Nagy C, Vinson J, Kirsch KL, Loehrer P. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest 2004; 22: 383-388.
Suckow MA, Gutierrez LS, Risatti CA, Wolter WR, Taylor RE, Pollard M, Navari RM, Castellino FJ, Paoni NF. The anti-ischemic agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice. Cancer Lett 2004; 209: 165-169. link
Navari RM. Aprepitant: A neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2004; 4: 715-724.
Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W. A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting: A Hoosier Oncology Group study. Support Care Cancer 2005; 13: 529-534. link
Navari RM, Province PS, Passik SD. Management of Nausea and Vomiting in Cancer Patients. In Cancer Management in Man: Biological Response Modifiers, Chemotherapy, Antibiotics, Hyperthermia, Supporting Measures Neoplastic Prevention, B Minev, (ed.), Kluwer Academic Publishers, Netherlands, 2005.
Navari RM. Advances in the treatment of chemotherapy-induced nausea and vomiting. Hospital Pharmacy Europe 2005; 20: 37-40.
Reinbolt RE, Shenk AM, White PH, Navari RM. Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Management 2005, in press.
Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opinion Emerging Drugs 2005, in press.
